LABU240802P147000
- 8.65
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Cantor Fitzgerald Raises Price Target on Regeneron Pharmaceuticals to $1,015 From $1,000
UBS Cuts Exact Sciences' Price Target to $61 From $66, Maintains Neutral Rating
Exact Sciences Analyst Ratings
Stifel Maintains Buy on Exact Sciences, Lowers Price Target to $82
Buy Rating Affirmed for Exact Sciences on Strong Financials and Promising Growth Catalysts
Evercore Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,150
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,182
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,125
Morgan Stanley Downgrades United Therapeutics(UTHR.US) to Hold Rating, Raises Target Price to $337
Oppenheimer Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $400
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $67 to $88
A Quick Look at Today's Ratings for United Therapeutics(UTHR.US), With a Forecast Between $280 to $400
Exact Sciences (EXAS) Gets a Buy From Stifel Nicolaus
Benchmark Co. Remains a Buy on Exact Sciences (EXAS)
United Therapeutics (UTHR) Gets a Buy From Oppenheimer
United Therapeutics Analyst Ratings
Ladenburg Thalmann Downgrades United Therapeutics to Neutral From Buy, $319 Price Target
Analysts' Opinions Are Mixed on These Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), United Therapeutics (UTHR) and Exact Sciences (EXAS)
Strong Q2 Performance and Growth Trajectory Justify Buy Rating for Exact Sciences
HSBC Adjusts Price Target on AbbVie to $215 From $185